Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time

Autor:	Riho Klement, Katja M. Hakkarainen, Juha Mehtälä, Vesa Lindström, Tiina M. Järvinen, Amy Leval
Rok vydání:	2019
Předmět:	Bendamustine Adult Male medicine.medical_specialty Kaplan-Meier Estimate registry History 21st Century survival Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Chemoimmunotherapy Internal medicine Epidemiology Medicine Humans Public Health Surveillance Registries Finland Aged Retrospective Studies Aged 80 and over Hematology Lymphocytic leukaemia Chlorambucil business.industry Age Factors Retrospective cohort study General Medicine Original Articles Middle Aged Leukemia Lymphocytic Chronic B-Cell Survival Analysis 3. Good health 030220 oncology & carcinogenesis chemoimmunotherapy Rituximab Female Original Article epidemiology business chronic lymphocytic leukaemia 030215 immunology medicine.drug
Zdroj:	European Journal of Haematology
ISSN:	1600-0609
Popis:	Objectives We aimed to describe treatment patterns of chronic lymphocytic leukaemia (CLL) patients in routine practice settings, compare overall survival and time‐to‐next‐treatment among patients treated in different time periods (2005‐2008, 2009‐2013, 2014‐2015), and explore associated factors. Methods This retrospective cohort study included adult CLL patients from the Finnish Hematology Registry. Results In total, 124 and 64 CLL patients received first‐ and second‐line treatments, respectively. The use of first‐ and second‐line treatments with bendamustine‐rituximab (BR) increased, while chlorambucil‐based treatments decreased over time. Patients treated in more recent years showed a trend towards longer first‐ and second‐line survival. A trend towards inferior overall survival was detected in first‐ and second‐line treatment with B/BR. First‐line time‐to‐next‐treatment was longer for patients treated in the later years towards 2015, while second‐line time‐to‐next‐treatment did not improve over time. Conclusions This study identified that improved treatment outcomes over time were likely influenced by patient characteristics and treatments, but also through other factors unexplored in this study. Hence, further research on the factors influencing patients’ survival over time is needed. In particular, research on using B/BR in clinical practice is warranted.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c417fc0c5b875b8a61b3479829f137 https://pubmed.ncbi.nlm.nih.gov/31210368 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.